Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study
Abstract
Immune-based therapy for metastatic breast cancer has had limited success, particularly in molecular subtypes with low somatic mutations rates. Strategies to augment T-cell infiltration of tumors include vaccines targeting established oncogenic drivers such as the genomic amplification of HER2. We constructed a vaccine based on a novel alphaviral vector encoding a portion of HER2 (VRP-HER2).
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- May 01, 2019
- Source ID
- 10.1158/1078-0432.ccr-18-3102
Entities
People
- Amy C. Hobeika
- André Rogatko
- Erika J Crosby
- Gloria Broadwater
- Herbert Kim Lyerly
- Holden T. Maecker
- Joshua C. Snyder
- Kimberly Blackwell
- Michael A. Morse
- Paul K Marcom
- Serena Chang
- Sung Jin Kim
- Takuya Osada
- Terry Hyslop
- Veronica Lubkov
- William Gwin
- Zachary C Hartman
Organizations
- Duke University Hospital
- National Cancer Institute
- National Center for Advancing Translational Sciences
- National Center for Research Resources
- National Institutes of Health
- Stanford University
- Susan G. Komen for the Cure
- United States Department of Defense
- University of Washington